Acurx announces ibezapolstat scientific poster and update on its pol iiic pipeline presented at eccmid 2023 scientific conference

A scientific poster highlighting a novel pharmacologic property of oral ibezapolstat for c. difficile infection likely related to its unique mechanism of action was presented at eccmid 2023 an update on the company's pre-clinical antibiotic program in lead optimization stage for systemic gram-positive bacterial infections was also presented ibezapolstat has previously received fda qidp and fast-track designation staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking